{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:09:30Z","timestamp":1781050170775,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["401512"],"award-info":[{"award-number":["401512"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78440-0","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:03:03Z","timestamp":1730854983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel approach to engineering three-dimensional bladder tumor models for drug testing"],"prefix":"10.1038","volume":"14","author":[{"given":"C. U.","family":"Monjaras-Avila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Luque-Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. V. M.","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chavez-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"3","key":"78440_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 71(3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA: A Cancer J. Clin."},{"key":"78440_CR2","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2023. Toronto, ON: Canadian Cancer Society; 2023. Available at: cancer.ca\/Canadian-Cancer-Statistics-2023-EN"},{"issue":"17","key":"78440_CR3","doi-asserted-by":"publisher","first-page":"E601","DOI":"10.1503\/cmaj.212097","volume":"194","author":"DR Brenner","year":"2022","unstructured":"Brenner, D. R. et al. Projected estimates of cancer in Canada in 2022. Can. Med. Assoc. J. 194(17), E601\u2013E607. https:\/\/doi.org\/10.1503\/cmaj.212097 (2022).","journal-title":"Can. Med. Assoc. J."},{"issue":"3","key":"78440_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BWG Van Rhijn","year":"2009","unstructured":"Van Rhijn, B. W. G. et al. Recurrence and progression of disease in non\u2013muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur. Urol. 56(3), 430\u2013442. https:\/\/doi.org\/10.1016\/j.eururo.2009.06.028 (2009).","journal-title":"Eur. Urol."},{"issue":"12","key":"78440_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers9020015","volume":"9","author":"S Gupta","year":"2017","unstructured":"Gupta, S., Gill, D., Poole, A. & Agarwal, N. Systemic immunotherapy for urothelial cancer: Current trends and future directions. Cancers 9(12), 15. https:\/\/doi.org\/10.3390\/cancers9020015 (2017).","journal-title":"Cancers"},{"issue":"21","key":"78440_CR6","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Von Der Maase","year":"2005","unstructured":"Von Der Maase, H. et al. Long-Term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23(21), 4602\u20134608. https:\/\/doi.org\/10.1200\/JCO.2005.07.757 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"78440_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis, M. et al. Randomized phase II\/III Trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 30(2), 191\u2013199. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"78440_CR8","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt, J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27(27), 4454\u20134461. https:\/\/doi.org\/10.1200\/JCO.2008.20.5534 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"78440_CR9","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","volume":"74","author":"JL Wilding","year":"2014","unstructured":"Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res. 74(9), 2377\u20132384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2971 (2014).","journal-title":"Cancer Res."},{"issue":"3","key":"78440_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3892\/etm.2014.1837","volume":"8","author":"J Ding","year":"2014","unstructured":"Ding, J. et al. Current animal models of bladder cancer: Awareness of translatability (Review). Exp. Ther. Med. 8(3), 691\u2013699. https:\/\/doi.org\/10.3892\/etm.2014.1837 (2014).","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"78440_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1517\/17460441.2014.902930","volume":"9","author":"PA Oliveira","year":"2014","unstructured":"Oliveira, P. A., Arantes-Rodrigues, R. & Vasconcelos-N\u00f3brega, C. Animal models of urinary bladder cancer and their application to novel drug discovery. Expert Opin. Drug Discov. 9(5), 485\u2013503. https:\/\/doi.org\/10.1517\/17460441.2014.902930 (2014).","journal-title":"Expert Opin. Drug Discov."},{"issue":"9","key":"78440_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrneph.2015.118","volume":"11","author":"MB Rookmaaker","year":"2015","unstructured":"Rookmaaker, M. B., Schutgens, F., Verhaar, M. C. & Clevers, H. Development and application of human adult stem or progenitor cell organoids. Nat. Rev. Nephrol. 11(9), 546\u2013554. https:\/\/doi.org\/10.1038\/nrneph.2015.118 (2015).","journal-title":"Nat. Rev. Nephrol."},{"issue":"7","key":"78440_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrurol.2017.65","volume":"14","author":"S Wang","year":"2017","unstructured":"Wang, S., Gao, D. & Chen, Y. The potential of organoids in urological cancer research. Nat. Rev. Urol. 14(7), 401\u2013414. https:\/\/doi.org\/10.1038\/nrurol.2017.65 (2017).","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"78440_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.juro.2012.12.106","volume":"190","author":"H Okuyama","year":"2013","unstructured":"Okuyama, H. et al. Involvement of Heregulin\/HER3 in the primary culture of human urothelial cancer. J. Urol. 190(1), 302\u2013310. https:\/\/doi.org\/10.1016\/j.juro.2012.12.106 (2013).","journal-title":"J. Urol."},{"issue":"10","key":"78440_CR15","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1073\/pnas.1803595116","volume":"116","author":"J Mullenders","year":"2019","unstructured":"Mullenders, J. et al. Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proc. Nat. Acad. Sci. 116(10), 4567\u20134574. https:\/\/doi.org\/10.1073\/pnas.1803595116 (2019).","journal-title":"Proc. Nat. Acad. Sci."},{"issue":"12","key":"78440_CR16","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier, L. et al. Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening. Nat. Med. 23(12), 1424\u20131435. https:\/\/doi.org\/10.1038\/nm.4438 (2017).","journal-title":"Nat. Med."},{"key":"78440_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejphar.2016.10.039","volume":"793","author":"Z Lin","year":"2016","unstructured":"Lin, Z., Zhang, Q. & Luo, W. Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. Eur. J. Pharmacol. 793, 76\u201381. https:\/\/doi.org\/10.1016\/j.ejphar.2016.10.039 (2016).","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"78440_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrurol.2017.19","volume":"14","author":"T Inoue","year":"2017","unstructured":"Inoue, T., Terada, N., Kobayashi, T. & Ogawa, O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nat. Rev. Urol. 14(5), 267\u2013283. https:\/\/doi.org\/10.1038\/nrurol.2017.19 (2017).","journal-title":"Nat. Rev. Urol."},{"issue":"16","key":"78440_CR19","doi-asserted-by":"publisher","first-page":"25928","DOI":"10.18632\/oncotarget.15237","volume":"8","author":"D Lin","year":"2017","unstructured":"Lin, D. et al. Metabolic heterogeneity signature of primary treatment-na\u00efve prostate cancer. Oncotarget 8(16), 25928\u201325941. https:\/\/doi.org\/10.18632\/oncotarget.15237 (2017).","journal-title":"Oncotarget"},{"issue":"8","key":"78440_CR20","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-08-4210","volume":"69","author":"VC Daniel","year":"2009","unstructured":"Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69(8), 3364\u20133373. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4210 (2009).","journal-title":"Cancer Res."},{"issue":"7921","key":"78440_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts, C. et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608(7921), 199\u2013208. https:\/\/doi.org\/10.1038\/s41586-022-04975-9 (2022).","journal-title":"Nature"},{"issue":"5","key":"78440_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.stem.2008.09.002","volume":"3","author":"M Eiraku","year":"2008","unstructured":"Eiraku, M. et al. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 3(5), 519\u2013532. https:\/\/doi.org\/10.1016\/j.stem.2008.09.002 (2008).","journal-title":"Cell Stem Cell"},{"issue":"1","key":"78440_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.678","volume":"12","author":"B Yuan","year":"2022","unstructured":"Yuan, B. et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin. Transl. Med. 12(1), e678. https:\/\/doi.org\/10.1002\/ctm2.678 (2022).","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"78440_CR24","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim, M. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10(1), 3991. https:\/\/doi.org\/10.1038\/s41467-019-11867-6 (2019).","journal-title":"Nat. Commun."},{"issue":"1","key":"78440_CR25","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","volume":"14","author":"M Minoli","year":"2023","unstructured":"Minoli, M. et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat. Commun. 14(1), 2214. https:\/\/doi.org\/10.1038\/s41467-023-37696-2 (2023).","journal-title":"Nat. Commun."},{"issue":"11","key":"78440_CR26","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.3390\/biomedicines11112958","volume":"11","author":"M Berndt-Paetz","year":"2023","unstructured":"Berndt-Paetz, M. et al. Cell line-based human bladder organoids with bladder-like self-organization\u2014a new standardized approach in bladder cancer research. Biomedicines 11(11), 2958. https:\/\/doi.org\/10.3390\/biomedicines11112958 (2023).","journal-title":"Biomedicines"},{"issue":"18","key":"78440_CR27","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1016\/j.biomaterials.2014.03.003","volume":"35","author":"LW Dunne","year":"2014","unstructured":"Dunne, L. W. et al. Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments. Biomaterials 35(18), 4940\u20134949. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.03.003 (2014).","journal-title":"Biomaterials"},{"issue":"6","key":"78440_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9(6), 338\u2013350. https:\/\/doi.org\/10.1038\/nrclinonc.2012.61 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"78440_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1078-0432.CCR-09-2878","volume":"16","author":"X Dong","year":"2010","unstructured":"Dong, X. et al. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16(5), 1442\u20131451. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2878 (2010).","journal-title":"Clin. Cancer Res."},{"key":"78440_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.976065","volume":"12","author":"S Genta","year":"2022","unstructured":"Genta, S., Coburn, B., Cescon, D. W. & Spreafico, A. Patient-derived cancer models: Valuable platforms for anticancer drug testing. Front. Oncol. 12, 976065. https:\/\/doi.org\/10.3389\/fonc.2022.976065 (2022).","journal-title":"Front. Oncol."},{"issue":"3","key":"78440_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194016","volume":"13","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Establishment of patient-derived tumor spheroids for non-small cell lung cancer. PLOS ONE 13(3), e0194016. https:\/\/doi.org\/10.1371\/journal.pone.0194016 (2018).","journal-title":"PLOS ONE"},{"issue":"6\u20137","key":"78440_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3727\/096368910X508753","volume":"19","author":"A Soto-Gutierrez","year":"2010","unstructured":"Soto-Gutierrez, A. et al. Cell delivery: From cell transplantation to organ engineering. Cell Transplant. 19(6\u20137), 655\u2013665. https:\/\/doi.org\/10.3727\/096368910X508753 (2010).","journal-title":"Cell Transplant."},{"key":"78440_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fbioe.2017.00034","volume":"5","author":"AC Destefani","year":"2017","unstructured":"Destefani, A. C., Sirtoli, G. M. & Nogueira, B. V. Advances in the knowledge about kidney decellularization and repopulation. Front. Bioeng. Biotechnol. 5, 34. https:\/\/doi.org\/10.3389\/fbioe.2017.00034 (2017).","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"6","key":"78440_CR34","first-page":"245","volume":"6","author":"PA Raven","year":"2018","unstructured":"Raven, P. A. et al. Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model. Am. J. Clin. Exp. Urol. 6(6), 245\u2013259 (2018).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"78440_CR35","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5902","author":"GS Kulkarni","year":"2019","unstructured":"Kulkarni, G. S. et al. Canadian urological association guideline: Muscle-invasive bladder cancer. Can. Urol. Assoc. J. https:\/\/doi.org\/10.5489\/cuaj.5902 (2019).","journal-title":"Can. Urol. Assoc. J."},{"issue":"Suppl_1","key":"78440_CR36","doi-asserted-by":"publisher","first-page":"D652","DOI":"10.1093\/nar\/gkp995","volume":"38","author":"SA Forbes","year":"2010","unstructured":"Forbes, S. A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38(Suppl_1), D652\u2013D657. https:\/\/doi.org\/10.1093\/nar\/gkp995 (2010).","journal-title":"Nucleic Acids Res."},{"issue":"7391","key":"78440_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603\u2013607. https:\/\/doi.org\/10.1038\/nature11003 (2012).","journal-title":"Nature"},{"issue":"10","key":"78440_CR38","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","volume":"84","author":"JI Johnson","year":"2001","unstructured":"Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84(10), 1424\u20131431. https:\/\/doi.org\/10.1054\/bjoc.2001.1796 (2001).","journal-title":"Br. J. Cancer"},{"issue":"513","key":"78440_CR39","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft, S. N. et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Trans. Med. 11(513), eaay2574. https:\/\/doi.org\/10.1126\/scitranslmed.aay2574 (2019).","journal-title":"Sci. Trans. Med."},{"issue":"1","key":"78440_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao, Y. et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26(1), 17-26.e6. https:\/\/doi.org\/10.1016\/j.stem.2019.10.010 (2020).","journal-title":"Cell Stem Cell"},{"issue":"1","key":"78440_CR41","doi-asserted-by":"publisher","first-page":"19909","DOI":"10.1038\/s41598-019-56356-4","volume":"9","author":"S-Y Kim","year":"2019","unstructured":"Kim, S.-Y. et al. Patient-derived cells to guide targeted therapy for advanced lung adenocarcinoma. Sci. Rep. 9(1), 19909. https:\/\/doi.org\/10.1038\/s41598-019-56356-4 (2019).","journal-title":"Sci. Rep."},{"issue":"2","key":"78440_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173(2), 515-528.e17. https:\/\/doi.org\/10.1016\/j.cell.2018.03.017 (2018).","journal-title":"Cell"},{"issue":"3","key":"78440_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","volume":"130","author":"BJ Viergever","year":"2024","unstructured":"Viergever, B. J. et al. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation. Br. J. Cancer 130(3), 369\u2013379. https:\/\/doi.org\/10.1038\/s41416-023-02494-6 (2024).","journal-title":"Br. J. Cancer"},{"issue":"3","key":"78440_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/cells12030508","volume":"12","author":"S Kowald","year":"2023","unstructured":"Kowald, S. et al. Novel zebrafish patient-derived tumor xenograft methodology for evaluating efficacy of immune-stimulating BCG therapy in urinary bladder cancer. Cells 12(3), 508. https:\/\/doi.org\/10.3390\/cells12030508 (2023).","journal-title":"Cells"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78440-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:04:33Z","timestamp":1730855073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78440"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78440-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4345624\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26883"}}